Who is sponsoring NCT06928974?

NCT06928974 is sponsored by Maria Sklodowska-Curie National Research Institute of Oncology.

What drugs are being tested in NCT06928974?

Interventions in NCT06928974: Bilateral Pedicled Vastus Lateralis Muscle Flaps Transposition.

What condition does NCT06928974 study?

NCT06928974 studies Prune Belly Syndrome.

Is NCT06928974 still recruiting?

NCT06928974 is currently active, enrolled. Last updated 15 April 2025.

Last reviewed 2025-04-15 · How we verify

NCT06928974

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Functional Abdominal Wall Reconstruction

Active, enrolled Last updated 15 April 2025

What this trial tests

trial testing Bilateral Pedicled Vastus Lateralis Muscle Flaps Transposition in Prune Belly Syndrome in 7 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 January 2017

Primary endpoint
1 March 2024

30 September 2026

Quick facts

Lead sponsor	Maria Sklodowska-Curie National Research Institute of Oncology
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	7
Start date	1 January 2017
Primary completion	1 March 2024
Estimated completion	30 September 2026
Sites	1 location across Poland

Drugs / interventions tested

Bilateral Pedicled Vastus Lateralis Muscle Flaps Transposition

Conditions studied

Prune Belly Syndrome — all drugs for Prune Belly Syndrome →

Sponsor

Maria Sklodowska-Curie National Research Institute of Oncology

Who can join

Under 18, any sex, with Prune Belly Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Assessement of outcomes of functional reconstruction of underdeveloped abdominal muscles with the use od pedicled Vastus Lateralis Muscle flaps.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Maria Sklodowska-Curie National Research Institute of Oncology trials

Trials by the same sponsor.

NCT07216157 — NoSeal Trial: Comparing Sealants Versus No Sealant for Preventing CSF Leak After Endonasal Skull Base Surgery · NA · recruiting
NCT06472583 — Preoperative Immunotherapy Combined With Stereotactic Radiation Therapy Boost in the Treatment of HER2-negative Breast C · Phase 2 · recruiting
NCT05271162 — Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines · Phase 3 · recruiting
NCT06201078 — Stereotactic Re-irradiation of Local Recurrences of Prostate Cancer After Radiotherapy · Phase 2 · recruiting
NCT06128863 — Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tiss · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06928974 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Maria Sklodowska-Curie National Research Institute of Oncology
Last refreshed: 15 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06928974.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing